Inovio Pharmaceuticals Inc (NASDAQ:INO)’s traded shares stood at 0.5 million during the last session, with the company’s beta value hitting 0.92. At the close of trading, the stock’s price was $1.96, to imply a decrease of -2.00% or -$0.04 in intraday trading. The INO share’s 52-week high remains $14.75, putting it -652.55% down since that peak but still an impressive 11.22% since price per share fell to its 52-week low of $1.74. The company has a valuation of $70.76M, with an average of 0.68 million shares in intraday trading volume over the past 10 days and average of 1.02 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Inovio Pharmaceuticals Inc (INO), translating to a mean rating of 2.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give INO a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.83.
Inovio Pharmaceuticals Inc (NASDAQ:INO) trade information
After registering a -2.00% downside in the last session, Inovio Pharmaceuticals Inc (INO) has traded red over the past five days. The 5-day price performance for the stock is -6.22%, and -14.04% over 30 days. With these gigs, the year-to-date price performance is 7.10%. Short interest in Inovio Pharmaceuticals Inc (NASDAQ:INO) saw shorts transact 3.5 million shares and set a 11.22 days time to cover.
The extremes give us $8 and $8 for target low and target high price respectively. As such, INO has been trading -308.16% off suggested target high and -308.16% from its likely low.
Inovio Pharmaceuticals Inc (INO) estimates and forecasts
The rating firms project that company’s revenue will shrink -84.92% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 25k. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 100k.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 13.49% for the past 5-year period. While 2025 is set for a 30.90% return in earnings, projections for the next 5 years are at 29.92% annually.
INO Dividends
Inovio Pharmaceuticals Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Inovio Pharmaceuticals Inc (NASDAQ:INO)’s Major holders
Inovio Pharmaceuticals Inc insiders hold 0.85% of total outstanding shares, with institutional holders owning 33.51% of the shares at 33.80% float percentage. In total, 33.51% institutions holds shares in the company, led by IFP ADVISORS, INC.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Inovio Pharmaceuticals Inc (INO) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 818.82 shares. This is just over 3.14% of the total shares, with a market valuation of $1.6 million. Data from the same date shows that the other fund manager holds a little less at 738.85, or 2.83% of the shares, all valued at about 1.45 million.
